We Offer Worldwide Shipping
Login Wishlist

Palmitoleic acid

$240

  • Brand : BIOFRON

  • Catalogue Number : BN-O1319

  • Specification : 98%(HPLC)

  • CAS number : 373-49-9

  • Formula : C16H30O2

  • Molecular Weight : 254.41

  • PUBCHEM ID : 445638

  • Volume : 0.1ml

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1319

Analysis Method

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

254.41

Appearance

Botanical Source

Structure Type

Category

SMILES

CCCCCCC=CCCCCCCCC(=O)O

Synonyms

9Z-hexadecenoic acid/hexadecenoic acid/Oleopalmitic acid/(9Z)-Hexadec-9-enoic acid/9-cis-Hexadecenoic acid/PALM ACID/PALMITOLEINSAEURE/(Z)-9-Hexadecenoic acid/(9Z)-9-Hexadecenoic acid/(9Z)-Hexadecenoic acid/cis-9-Hexadecenoic Acid/cis-Palmitoleic acid/9-Hexadecenoic acid, (9Z)-/Palmitoleic acid/9-Hexadecenoic acid/Zoomaric acid/(Z)-Palmitoleic acid/9-Hexadecenoic acid, (Z)-/Zoomeric acid/16:1n-7/(Z)-Hexadec-9-enoic acid

IUPAC Name

(Z)-hexadec-9-enoic acid

Density

0.9±0.1 g/cm3

Solubility

Flash Point

239.2±14.4 °C

Boiling Point

363.6±0.0 °C at 760 mmHg

Melting Point

0.5 °C

InChl

InChl Key

SECPZKHBENQXJG-FPLPWBNLSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:373-49-9) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

28980402

Abstract

Although dietary fatty acids can modulate metabolic and immune responses, the effects of palmitoleic acid (16:1n-7) remain unclear. Since this monounsaturated fatty acid is described as a lipokine, studies with cell culture and rodent models have suggested it enhances whole body insulin sensitivity, stimulates insulin secretion by β cells, increases hepatic fatty acid oxidation, improves the blood lipid profile, and alters macrophage differentiation. However, human studies report elevated blood levels of palmitoleic acid in people with obesity and metabolic syndrome. These findings might be reflection of the level or activity of stearoyl-CoA desaturase-1, which synthesizes palmitoleate and is enhanced in liver and adipose tissue of obese patients. The aim of this review is to describe the immune-metabolic effects of palmitoleic acid observed in cell culture, animal models, and humans to answer the question of whether palmitoleic acid is a plausible nonpharmacological strategy to prevent, control, or ameliorate chronic metabolic and inflammatory disorders. Despite the beneficial effects observed in cell culture and in animal studies, there are insufficient human intervention studies to fully understand the physiological effects of palmitoleic acid. Therefore, more human-based research is needed to identify whether palmitoleic acid meets the promising therapeutic potential suggested by the preclinical research.

© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

KEYWORDS

atherosclerosis; inflammation; lipokine; metabolic syndrome; monounsaturated fatty acid; nonalcoholic fatty liver disease; palmitoleic acid

Title

Is Palmitoleic Acid a Plausible Nonpharmacological Strategy to Prevent or Control Chronic Metabolic and Inflammatory Disorders?

Author

de Souza CO1, Vannice GK2, Rosa Neto JC1, Calder PC3,4.

Publish date

2018 Jan

PMID

27925195

Abstract

BACKGROUND:
Palmitoleic acid, since described as lipokine, increases glucose uptake by modulation of 5’AMP-activated protein kinase (AMPK), as well as increasing lipolysis by activation of peroxisome proliferator-activated receptor-α (PPARα), in adipose tissue. However, in liver, the effects of palmitoleic acid on glucose metabolism and the role of PPARα remain unknown.

OBJECTIVE:
To investigate whether palmitoleic acid improved the hepatic insulin sensitivity of obese mice.

METHODS:
C57BL6 and PPARα knockout (KO) mice were fed for 12 weeks with a standard diet (SD) or high-fat diet (HF), and in the last 2 weeks were treated with oleic or palmitoleic acid.

RESULTS:
Palmitoleic acid promoted a faster uptake of glucose in the body, associated with higher insulin concentration; however, even when stimulated with insulin, palmitoleic acid did not modulate the insulin pathway (AKT, IRS). Palmitoleic acid increased the phosphorylation of AMPK, upregulated glucokinase and downregulated SREBP-1. Regarding AMPK downstream, palmitoleic acid increased the production of FGF-21 and stimulated the expression of PPARα. Palmitoleic acid treatment did not increase AMPK phosphorylation, modulate glucokinase or increase FGF-21 in liver of PPARα KO mice.

CONCLUSIONS:
In mice fed with a high-fat diet, palmitoleic acid supplementation stimulated the uptake of glucose in liver through activation of AMPK and FGF-21, dependent on PPARα. J. Cell. Physiol. 232: 2168-2177, 2017. © 2016 Wiley Periodicals, Inc.

© 2016 Wiley Periodicals, Inc.

Title

Palmitoleic Acid Improves Metabolic Functions in Fatty Liver by PPARα-Dependent AMPK Activation.

Author

de Souza CO1, Teixeira AAS1, Biondo LA1, Lima Junior EA1, Batatinha HAP1, Rosa Neto JC1.

Publish date

2017 Aug

PMID

28096141

Abstract

The monounsaturated fatty acid palmitoleate (palmitoleic acid) is one of the most abundant fatty acids in serum and tissues, particularly adipose tissue and liver. Its endogenous production by stearoyl-CoA desaturase 1 gives rise to its cis isoform, cis-palmitoleate. Although trans-palmitoleate is also synthesized in humans, it is mainly found as an exogenous source in ruminant fat and dairy products. Recently, palmitoleate was considered to be a lipokine based on evidence demonstrating its release from adipose tissue and its metabolic effects on distant organs. After this finding, research has been performed to determine whether palmitoleate has beneficial effects on metabolism and to elucidate the underlying mechanisms. Thus, the aim of this work was to review the current status of knowledge about palmitoleate, its metabolism, and its influence on metabolic abnormalities. Results have shown mixed cardiovascular effects, direct or inverse correlations with obesity, and hepatosteatosis, but a significant amelioration or prevention of insulin resistance and diabetes. Finally, the induction of palmitoleate release from adipose tissue, dietary intake, and its supplementation are all interventions with a potential impact on certain metabolic diseases.

© 2017 American Society for Nutrition.

KEYWORDS

cardiovascular disease; diabetes; diet; fatty acids; insulin resistance; lipokine; obesity; palmitoleate

Title

The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease.

Author

Frigolet ME1, Gutierrez-Aguilar R2,3.

Publish date

2017 Jan 17


Description :

Empty ...